A subsequent systemic review argued that silymarin combined with antiviral drugs significantly reduced the level of serum transaminases, hepatic fibrosis markers, and serum transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 versus antiviral drugs in patients with CHB [28]. The gene discussed is IL6; the disease is Hepatic fibrosis.